Also known as: palmitoylethanolamide, PEA, palmidrol, micronized palmitoylethanolamide, Levagen
Latest evidence update: 2025-07-01
Strongest in Consistency (95). Held back by Sample size (58).
Mostly meta-analyses and well-designed RCTs.
Good cross-study replication, some imprecision.
Thousands of participants across the literature.
Studies agree on direction of effect.
Most studies are recent (last 2-3 years).
No quantified outcomes yet. Once we have studies with measurable endpoints, you will see per-outcome magnitude here.
Areas where research points to a consistent direction of effect. The strength of evidence is graded; the size of the effect is not quantified.
Recommended: 300 to 600 mg micronized or ultramicronized palmitoylethanolamide daily. Pain relief builds over 4 to 8 weeks.
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.